Bristol Myers Buys Nvidia Vera Rubin AI Computing System
Bristol Myers Squibb is the first life sciences firm to acquire Nvidia's Vera Rubin DGX SuperPOD to enhance its drug development. The drugmaker aims to increase research capacity and reduce testing timelines by up to 50% while improving energy efficiency.
X24 PerspectiveRelated Assets:
X24 Perspective